Used in pharmaceutical research as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK9, which plays a key role in transcription regulation. This compound shows promise in oncology for targeting cancer cells by disrupting the transcriptional machinery, leading to apoptosis in tumor cells. It is investigated for use in hematological malignancies and solid tumors due to its ability to suppress short-lived oncoproteins. Additionally, its structure allows for blood-brain barrier penetration, making it a candidate for central nervous system-involved cancers. Also employed as a biochemical tool in studies of kinase signaling pathways and gene expression control.